3 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Completed 1 |
Follow Werewolf Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma WTX-330 - Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Werewolf Therapeutics, Inc. | 24 | 2025-04-21 | 2026-10-19 |
| WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma WTX-330 - Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma | Phase 1 | Completed | Werewolf Therapeutics, Inc. | 25 | 2022-12-06 | 2026-01-06 |
| Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors WTX-124, pembrolizumab - Metastatic Solid Tumor, Advanced Solid Tumor | Phase 1 | Completed | Werewolf Therapeutics, Inc. | 156 | 2022-08-15 | 2026-10-09 |
Neoplasms (3) · Lymphoma, Non-Hodgkin (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Melanoma, Cutaneous Malignant (1) · Neoplasm Metastasis (1)
pembrolizumab (1)
United States (3)